The Dangers of Electronic Cigarettes: A Call for Regulation

Aug.29.2022
The Dangers of Electronic Cigarettes: A Call for Regulation
Electronic cigarette use in Brazil raises concerns despite the country's effective tobacco control policies. Potential health risks exist.

In recent years, electronic cigarettes have gained a lot of attention online, causing many people to have doubts about their safety. Despite Brazil's ban on the production and sale of electronic cigarettes since 2009, their usage has significantly increased in recent years due to their easy availability on both websites and physical storefronts.


Brazil is known as a global model for tobacco control public policy. Policies implemented over the years from 1989 to 2019 have reduced tobacco consumption among those aged 18 and over by about 60%. Some of these policies prevented children and adolescents from accessing tobacco products, thus preventing them from smoking. However, unlike all efforts to reduce smoking through public health, a new smoking trend emerged: electronic cigarettes. This includes a nicotine release device, whose first prototype was created in Pennsylvania in 1963, but it was never commercialized. In 2003, electronic cigarettes were created in China and spread around the world a decade later after a major tobacco industry company acquired a patent for them.


Many young people are drawn to the various formats, designs, and flavors of electronic cigarettes, making up a significant proportion of e-cigarette users. Research shows that in Brazil, one in five young people aged 18-24 have already used e-cigarettes. Additionally, 80% of those who use e-cigarettes are between the ages of 18 and 34. However, studies indicate that apart from nicotine, the aerosol may also contain other irritants and toxic substances such as formaldehyde, acrolein, diethylene glycol, acetaldehyde, benzene, and low doses of carcinogens. Tests on cells, tissues, and small animals exposed to liquids from different brands of e-cigarettes indicate that they are toxic to neurological, respiratory, and cardiovascular cells and may have adverse effects and cause birth defects during critical stages of fetal development.


The safety of electronic nicotine delivery systems has not been scientifically proven. In fact, the amount of nicotine dispensed by different e-cigarette devices can vary greatly, exposing consumers to much higher doses of the substance than traditional cigarettes. Reports have linked multiple incidents of severe burns, dismemberment and even death to explosions of e-cigarette batteries, dependent on the device's position at the time of detonation.


Although there is a lack of research evaluating the long-term consequences of inhaled substances from these devices, it is well-known that in the short-term, they may trigger or exacerbate symptoms of previously existing conditions such as coughing, asthma, chronic obstructive pulmonary disease (COPD), and hypertension. Additionally, in 2019, a series of severe cases of lung illness related to the use of electronic cigarettes, known as EVALI, was reported in the United States. By 2020, these cases resulted in over 2,800 hospitalizations, with many in intensive care units, and 68 deaths. The majority of cases were in young people, with one patient requiring a lung transplant.


Although the tobacco industry has attempted to convey the idea that e-cigarettes can aid in quitting smoking, this is not a good strategy. E-cigarette use operates through the same mechanism as traditional cigarettes, providing the brain with a nicotine rush. This explains why over 80% of those who use e-cigarettes to quit smoking still rely on nicotine (and e-cigarettes) after a year of follow-up. Scientifically proven and effective behavioral and pharmacological therapies are available to help quit smoking.


Since 2009, the use of electronic cigarettes has been prohibited in Brazil and will continue to be banned. However, children and teenagers are still able to obtain them, and the rate of experimentation is increasing daily. It is time to acknowledge that electronic cigarettes are not just vaporizers and to implement monitoring and restrictions on their sales.


Statement:


This article is compiled from third-party information and is intended only for industry exchange and learning.


This article does not represent the views of 2FIRSTS, and 2FIRSTS is unable to confirm the authenticity and accuracy of the content. The compilation of this article is only intended for industry discussion and research.


Due to limitations in our translation abilities, the translated article may not fully convey the original meaning. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on all domestic, Hong Kong, Macau, Taiwan, and foreign related statements and positions.


The compilation of information is owned by the original media and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

India Duty-Free Nicotine Pouch Sales Face Regulatory Test as ZYN, FOX Classification Remains Open
India Duty-Free Nicotine Pouch Sales Face Regulatory Test as ZYN, FOX Classification Remains Open
The Bombay High Court has ruled that airport duty-free shops are not exempt from India's domestic regulatory laws merely because they operate beyond the customs barrier, leaving in place a sales halt covering ZYN and FOX nicotine pouches at Mumbai's international airport. The court, however, did not determine that the products necessarily qualify as "drugs" under India's Drugs and Cosmetics Act. The retailers have four weeks to submit product information to the appropriate authorities, including CDSCO, which must complete its review within 30 days of receiving the submissions.
Sep.24
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As regulators pay closer attention to child safety in nicotine pouches, manufacturers face a practical challenge: how to strengthen child-resistant packaging without unnecessarily reworking products, production lines and regulatory submissions already in place. In a written interview with 2Firsts, Chemular detailed Safeguard’s external packaging approach, its customer-specific testing requirements and possible PMTA pathways. The model remains early-stage, but it offers a new way to think about an increasingly important regulatory and manufacturing issue.
Industry Insight
Sep.19
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
FDA CTP Director Bret Koplow used his FDLI keynote in Washington to outline how the agency is rethinking the PMTA framework. He discussed category-specific review, nicotine pouch and sPMTA pilots, AI-assisted review, a 70% reduction in pending applications, and a major staffing constraint: CTP currently has only nine scientific review teams. He also reaffirmed tobacco harm reduction while stressing youth protection, flavored products, risk communication, and the challenge of unauthorized e-cigarettes.
Regulations
Oct.06
Product | JT Launches Three Autumn-Limited Ploom Tobacco Sticks in Japan Across EVO, MEVIUS and CAMEL Brands
Product | JT Launches Three Autumn-Limited Ploom Tobacco Sticks in Japan Across EVO, MEVIUS and CAMEL Brands
Japan Tobacco Inc. (JT) launched three limited-edition autumn tobacco sticks for its Ploom heated tobacco devices in Japan on October 16, 2026, under the EVO, MEVIUS and CAMEL brands. All three are regular tobacco variants with seasonal packaging. Each pack contains 20 sticks, priced at ¥620, ¥590 and ¥570, respectively, including tax. The products are compatible with all Ploom devices and are sold in limited quantities exclusively through the CLUB JT online store while supplies last.
product
Oct.20
UK Vape Duty Starts in October as Hayati, DOJO and Others Launch Lower-Capacity Products With Lower Per-Unit Tax
UK Vape Duty Starts in October as Hayati, DOJO and Others Launch Lower-Capacity Products With Lower Per-Unit Tax
The UK's Vaping Products Duty will take effect on October 1, 2026, at a flat rate of £2.20 per 10ml of vaping liquid. Ahead of implementation, DOJO, PIXL and Hayati have introduced or been reported to be adding lower-capacity tiers alongside larger products. DOJO has added a 6ml BLAST7K Fresh below its 10ml BLAST10K Fresh, PIXL offers both a 12ml 8000 and a 6ml 5K, while retailer Ninja Vapes says Hayati is preparing a 7ml 4K alongside its existing 12ml 6K. The pattern points to a growing lower-capacity tier in the UK market, although the brands have not all explicitly linked the changes to the new duty.
Sep.23